FDA 483 - Dasami Lab Private Limited - June 01, 2018

Dasami Lab Private Limited, an API manufacturer, was inspected by the FDA and received a Form 483 with four observations. The inspection revealed deficiencies in stability data for drug substances, lack of equipment log books, inadequate analytical method transfers and verifications, and an insufficient power failure procedure. These issues indicate a need for improved quality control and documentation practices.